Varex director sells EUR 129k while Teledyne caps the stock

Teledyne set the ceiling, not the market

The stock has not been trading like a sleepy medtech supplier. It has been trading like a pending takeout, because that is what it is. Teledyne agreed in August to buy Varex for $18.90 a share in cash, and Varex has spent mid-September hovering around $18.47 to $18.49, close enough to the bid that the market is mostly arguing about closing mechanics, not valuation discovery.

That matters because the insider sale is not happening in a vacuum. Medical imaging and the broader medtech equipment group have lagged the S&P 500 this year, with hospital volumes soft, tariff noise still hanging around the sector, and capital rotating toward cleaner defensive names. Varex is an odd fit inside that backdrop. It is a specialized supplier of X-ray tubes, detectors, and components, not a broad platform company, and its recent strength comes less from operating momentum than from the Teledyne deal.

The relevant comparison is not some abstract healthcare basket. It is Varex against larger imaging platforms like GE HealthCare and Siemens Healthineers, and against a smaller, more cyclical medtech name like Envista Holdings. Those names help frame the point. The big integrated platforms have scale and recurring service revenue. The smaller equipment names tend to trade on execution and balance-sheet discipline. Varex sits in the awkward middle, and the bid from Teledyne has temporarily flattened that distinction.

Kunkel sold into a stock already near the bid

Jay K. Kunkel, a director at Varex, sold 8,121 shares on September 14 at $18.48 a share, for about EUR 129,471 in euro-normalised filing value. The filing reported the next day shows his direct holdings fell to 15,329 shares afterward, and no 10b5-1 plan was indicated. That is a real sale, not a footnote. It is also a sale into a stock that had already done most of the work for him.

The price matters more than the headline size. $18.48 is only a touch below the $18.90 cash consideration Teledyne agreed to pay, which means Kunkel was not selling into a deep discount or a panic tape. He was selling into a market that had already marked Varex up to deal territory. That is the kind of context that keeps a director sale from being read as a broad negative on the business. It is also why you do not want to overread it as a heroic tell. The stock is already doing a lot of the signaling for you.

The filing also sits inside a broader cluster. CFO Shubham Maheshwari sold 130,000 shares on September 11 at a weighted average of about $18.46, roughly $2.4 million, primarily to cover taxes on option exercises. That is the larger print. Kunkel’s sale is the smaller follow-through. Together they make the pattern too coordinated to treat as random housekeeping, even if the mechanics differ. One was tied to option exercise taxes. The other was a straight open-market sale.

The insider cluster and what it says

Insiders Trades data flags this as a cluster, and that is the useful part of the internal read. Three distinct insiders have traded the name in a short window, with seven recent declarations in the cluster record. The recent list includes Kunkel’s September 14 sale, Maheshwari’s September 11 sale, and earlier August activity from Karen L. Aranki. That is enough to say the board and senior management are not sitting still while the stock trades near the bid.

Our scoring leans on a few things that matter here. The filing came from an operating director. It was part of a multi-insider cluster. The euro-normalised filing value was about EUR 129,471, and that sits at roughly 0.02% of the company’s market value. In a small or mid-cap name, that kind of relative size is the sort of thing our framework pays attention to. It is not because the number is huge in absolute terms. It is because it is large enough to show intent, but small enough to fit the usual post-rally trim pattern.

The historical cohort read is the one place where the internal data adds something a plain filing recap cannot. For director-level buys at sweet-spot names, our cohort data shows a 53% win rate at 90 days and a 3.95% average return over that horizon, with a much larger 83.58% average return over 365 days. That is a historical bucket, not a promise, and it is not even the same direction as this trade. Still, it tells you why role and size matter. A director filing at a sub-billion-euro market value name has historically been a better hunting ground than a random headline sale at a mega-cap. Varex is not a random headline sale. It is a director sale inside a cluster, in a stock already pinned near a cash bid.

Why Varex behaves differently from GE HealthCare

Varex is not being valued like a standalone growth story right now. It is being valued like a deal. That changes the comparison set. GE HealthCare and Siemens Healthineers are judged on installed base, service mix, and the pace of imaging demand. Varex is judged on whether Teledyne closes and whether the spread is worth the wait. Those are different trades.

The company’s recent quarter did not change that. Varex reported non-GAAP EPS of $0.31, ahead of expectations, on revenue of $210.5 million, which missed. It also turned profitable year over year. That is a decent operating print, but in a stock with a pending acquisition, the market usually files that under support, not re-rating catalyst. The deal premium does the heavy lifting. The quarter just keeps the story from falling apart.

The medical segment still matters because it is the bulk of the business. Recent quarterly medical net sales were around $435 million, and that tells you what Teledyne is buying, beyond the headline. It is buying a specialized component supplier tied to imaging systems, not a consumer-facing brand or a software layer. That makes the company strategically useful, but it also means the stock’s current price is less about the next quarter and more about whether the transaction clears approvals and closes in early 2027, as reported.

What the stock price is already telling you

Varex has outperformed many peers this year, with gains near 59 percent, and that is mostly the takeover premium talking. The stock’s 52-week range, from $9.09 to $18.63, shows how much of the move has already happened. When a name is sitting within pennies of the bid, the market is not rewarding new information very generously. It is waiting for paperwork.

That is why the insider sale reads differently here than it would in a normal operating company. In a non-deal situation, a director sale near a 52-week high can still be read as a valuation check. Here, the stock is already anchored by a cash offer. Kunkel’s sale at $18.48 says he was willing to monetize into that anchor. Maheshwari’s larger sale says the same thing, though with a tax-driven explanation attached. Put together, they tell you the insiders are comfortable realizing value at current levels rather than waiting for a few extra cents of spread compression.

The market backdrop helps explain why this is happening now. Healthcare has kept its defensive reputation, but medtech equipment and supplies have not kept pace with the broader market rally. PitchBook’s sector work and other healthcare commentary point to a year where the market has favored the cleaner, larger, and more recurring revenue names. Varex is not getting that kind of multiple support. It is getting a bid from Teledyne, and that bid has become the whole story.

Why the small-cap filing still matters

Insider behavior matters more in smaller names because the market is less efficient at pricing the information content of a filing. That is the basic reason our framework gives weight to the size bucket. Varex sits in the sweet spot, with a market value around EUR 675.96 million, where a director sale can still matter even if the absolute euro amount is not enormous. The filing is not about balance-sheet stress. It is about timing, liquidity, and how insiders choose to monetize when the stock has already moved.

The fundamental screen is not screaming quality here. Insiders Trades data puts the company’s fundamental score at 35, with a rank of 21,663 out of 29,065. That is not a disaster, but it is not the kind of operating profile that would make you ignore the filing and buy the stock on fundamentals alone. In a normal setup, that would be a warning sign. In this setup, it mostly tells you the deal premium is doing the work that fundamentals are not.

You can see the tension in the peer set. GE HealthCare and Siemens Healthineers are larger, more diversified, and more insulated from single-transaction outcomes. Envista is closer in size and medtech cyclicality, but it does not have a cash bid sitting over the stock. Varex is the one with the cleanest exit path and the least room for a long debate about intrinsic value. That is why the insider cluster matters, even if the stock is already near the offer. It tells you the people filing are behaving like holders of a near-finished trade, not like owners of a long-duration compounder.

What you still have to watch before the deal closes

The obvious risk is that the spread to $18.90 does not close on schedule. Teledyne still needs approvals, and the expected early 2027 close leaves room for headlines, delays, and the usual transaction friction. If the deal drifts, the stock can move on nothing more than timing anxiety. That is the part of the setup that still matters more than the insider sale itself.

The second risk is that the market starts to care again about the underlying business. That would be unusual while the bid is live, but not impossible if the transaction path gets noisier. Varex’s latest quarter was mixed, with the EPS beat offset by a revenue miss. If the deal were to wobble, those numbers would matter more than they do now. For the moment, they are background.

The third thing to watch is whether more insiders file while the stock remains near the bid. One sale can be explained. Two sales can be contextualized. A continuing cluster would tell you the same thing in louder language. For now, the pattern is already clear enough. Kunkel sold. Maheshwari sold. The stock is sitting near the Teledyne price. You do not need a grand theory to read that combination.

The comparison that actually holds up

Varex against GE HealthCare is a comparison of scale and business quality. Varex against Envista is a comparison of size and cyclicality. Varex against itself, before the Teledyne bid, is the comparison that matters most now. The company used to trade on execution and medtech demand. It now trades on deal completion and spread management. That is a different market, and the insider filings belong to that market.

The cleanest conclusion is not that the sales are bearish in some broad sense. They are more specific than that. A director sold 8,121 shares at $18.48. The CFO sold 130,000 shares days earlier. The stock is near the $18.90 cash bid. The sector is still lagging, the company’s fundamentals are middling, and the takeover premium has already done most of the valuation work. That is enough to make the filings worth your attention, and enough to keep you from pretending they say more than they do.

The next real catalyst is not another insider form. It is the next update on Teledyne’s path to closing, because that is what still governs the stock.

Dig deeper: Varex Imaging Corp's full insider filing history.

This is not investment advice.